GlassScriptPhysician profile
Jeffrey M Montgomery
NPI 1902007990
$40,218.71
in general payments reported to CMS, 2019-2025
52 companies · $7,865 in 2025
The $7,865 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,024 · 2020: $5,623 · 2021: $13K · 2022: $5,385 · 2023: $2,824 · 2024: $2,528 · 2025: $7,865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,886 · Consulting Fee: $4,313 · Education: $17.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,885.69 |
| Consulting Fee | $4,312.50 |
| Education | $17.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $16,377.61 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $6,298.00 | 2021-2025 | |
| Novo Nordisk INC | $2,845.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,008.67 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $1,648.18 | 2019-2025 | |
| Lilly USA, LLC | $1,547.92 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,488.24 | 2019-2025 | Jardiance, Tradjenta, Stiolto Respimat |
| Allergan, INC. | $1,058.61 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $803.66 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $654.75 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Janssen Pharmaceuticals, INC | $473.15 | 2019-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $447.29 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $440.39 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Teva Pharmaceuticals USA, INC. | $337.53 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Kowa Pharmaceuticals America, INC. | $282.63 | 2019-2025 | Zoryve, Livalo, Seglentis |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Montgomery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.